Correction of Liver Steatosis by a Hydrophobic Iminosugar Modulating Glycosphingolipids Metabolism

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lombardo, Elisa ^a   van Roomen, Cindy P A A ^a   van Puijvelde, Gijs H ^b   Ottenhoff, Roelof ^a   van Eijk, Marco ^a   Aten, Jan ^a   Kuiper, Johan ^b   Overkleeft, Herman S ^c   Groen, Albert K ^d   Verhoeven, Arthur J ^a   Aerts, Johannes M F G ^a   Bietrix, Florence ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLYCOSPHINGOLIPID; IMINOSUGAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL INTAKE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; HEPATITIS; HYDROPHOBICITY; LIPID BLOOD LEVEL; LIPID DIET; LIPOGENESIS; LIVER FIBROSIS; LIVER WEIGHT; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; WEIGHT REDUCTION;

1-DEOXYNOJIRIMYCIN; ACTINS; ADAMANTANE; ANIMALS; APOLIPOPROTEIN E3; CELL MEMBRANE; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FATTY LIVER; FEMALE; GENE EXPRESSION; GLYCOSPHINGOLIPIDS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMINO SUGARS; IMMUNOHISTOCHEMISTRY; INSULIN; LIPID METABOLISM; LIVER; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SMOOTH; OXIDATION-REDUCTION; RECEPTORS, LDL;

EID: 84867327154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038520     Document Type: Article

References (42)

1. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, et al. (2009) Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 41: 969-976.
2. McCullough AJ, (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 Suppl 1: S17-S29.
3. Solga SF, Alkhuraishe A, Cope K, Tabesh A, Clark JM, et al. (2006) Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers 11: 174-183.
4. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873.
5. Lewis JR, Mohanty SR, (2010) Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55: 560-578.
6. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, et al. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48: 474-486.
7. Vinaixa M, Rodriguez MA, Rull A, Beltran R, Blade C, et al. (2010) Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J Proteome Res 9: 2527-2538.
8. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, et al. (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56: 1210-1218.
9. Bijl N, Sokolovic M, Vrins C, Langeveld M, Moerland PD, et al. (2009) Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 50: 1431-1441.
10. Yew NS, Zhao H, Hong EG, Wu IH, Przybylska M, et al. (2010) Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One 5: e11239.
11. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, et al. (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56: 1341-1349.
12. van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CP, et al. (2009) Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 4: e4723.
13. Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, et al. (2009) Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50: 85-93.
14. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, et al. (2003) Enhanced insulinsensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A 100: 3445-3449.
15. Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, et al. (2007) Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci U S A 104: 13678-13683.
16. Wennekes T, van den Berg RJ, Boot RG, van der Marel GA, Overkleeft HS, et al. (2009) Glycosphingolipids-nature, function, and pharmacological modulation. Angew Chem Int Ed Engl 48: 8848-8869.
17. Langeveld M, Aerts JM, (2009) Glycosphingolipids and insulin resistance. Prog Lipid Res 48: 196-205.
18. Wennekes T, Meijer AJ, Groen AK, Boot RG, Groener JE, et al. (2010) Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem 53: 689-698.
19. Brown MS, Goldstein JL, (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7: 95-96.
20. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA, (2007) Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 178: 6557-6566.
21. Larter CZ, Yeh MM, (2008) Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23: 1635-1648.
22. Rull A, Rodriguez F, Aragones G, Marsillach J, Beltran R, et al. (2009) Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine 48: 273-279.
23. Bietrix F, Lombardo E, van Roomen CP, Ottenhoff R, Vos M, et al. (2010) Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 30: 931-937.
24. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, et al. (2010) Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 32: 769-775.
25. Langeveld M, van den Berg SA, Bijl N, Bijland S, van Roomen CP, et al. (2012) Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation. Metabolism 61: 99-107.
26. Tsuduki T, Nakamura Y, Honma T, Nakagawa K, Kimura T, et al. (2009) Intake of 1-deoxynojirimycin suppresses lipid accumulation through activation of the beta-oxidation system in rat liver. J Agric Food Chem 57: 11024-11029.
27. Kobayashi Y, Miyazawa M, Kamei A, Abe K, Kojima T, (2010) Ameliorative effects of mulberry (Morus alba L.) leaves on hyperlipidemia in rats fed a high-fat diet: induction of fatty acid oxidation, inhibition of lipogenesis, and suppression of oxidative stress. Biosci Biotechnol Biochem 74: 2385-2395.
28. Jennemann R, Rothermel U, Wang S, Sandhoff R, Kaden S, et al. (2010) Hepatic glycosphingolipid deficiency and liver function in mice. Hepatology 51: 1799-1809.
29. Shen C, Bullens D, Kasran A, Maerten P, Boon L, et al. (2004) Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. Int Immunopharmacol 4: 939-951.
30. Lee AH, Scapa EF, Cohen DE, Glimcher LH, (2008) Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496.
31. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, et al. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306: 457-461.
32. Ozcan L, Tabas I, (2012) Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annu Rev Med 63: 317-328.
33. Boslem E, MacIntosh G, Preston AM, Bartley C, Busch AK, et al. (2011) A lipidomic screen of palmitate-treated MIN6 β-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking. Biochem J 435: 267-76.
34. Li Z, Soloski MJ, Diehl AM, (2005) Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42: 880-885.
35. Kremer M, Thomas E, Milton RJ, Perry AW, van RN, et al. (2010) Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 51: 130-141.
36. Marí M, Caballero F, Colell A, Morales A, Caballeria J, et al. (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4: 185-198.
37. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, et al. (2011) Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141: 1393-1403.
38. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJ, de Winther MP, et al. (2010) Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 138: 2477-2486, 2477-86-2486.
39. Overkleeft HS, Renkema GH, Neele J, Vianello P, Hung IO, et al. (1998) Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem 273: 26522-26527.
40. Wennekes T, van den Berg RJ, Donker W, van der Marel GA, Strijland A, et al. (2007) Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem 72: 1088-1097.
41. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
42. Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ, (2003) Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 31: 1647-1653.